Lymphomas & Lymphoid NeoplasiaTopic Compilations Lymphomas & Lymphoid Neoplasia Monday, January 3, 2000 A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia. Comparing Tisa-Cel to Standard of Care in Relapsed/Refractory Aggressive B-Cell NHL As a second-line treatment for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL), the autologous CD19-targeting chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (tisa-cel) led to... Adding Polatuzumab Vedotin to R-CHP Reduces Risk of Disease Progression or Death in Newly... Treatment with polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) led to a 27% reduction in the relative risk of disease... ctDNA: A Noninvasive Tool for Diagnosis and Outcome Prediction in CNS Lymphomas Circulating tumor DNA (ctDNA) accurately reflects tumor burden and may serve as a useful clinical biomarker for risk, outcome, and surgery-free lymphoma classification in... Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise in Relapsed/Refractory B-Cell NHL The CD20xCD3 bispecific antibody mosunetuzumab, in combination with the anti-CD79b antibody drug conjugate polatuzumab vedotin, was safe and efficacious for the treatment of patients... ZUMA-7: Benefits of Axi-Cel Persist Over Current Standard of Care in Aggressive B-Cell Lymphoma The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and clinically meaningful improvement in event-free survival (EFS) compared with second-line standard... Could Liso-cel Become a New Second-Line Standard for Relapsed/Refractory LBCL? Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel) significantly improved event-free survival (EFS) compared with standard of care in patients with large... High-Dose Methotrexate Does Not Reduce CNS Relapse in Aggressive B-cell Lymphoma High-dose methotrexate did not reduce secondary central nervous system (SCNS) lymphoma events in patients with high-risk B-cell lymphoma, according to the results of an... Comparing AHCT Versus CAR T-Cell Therapy in Relapsed DLBCL Compared with chimeric antigen receptor (CAR) T-cell therapy, autologous hematopoietic cell transplantation (AHCT) led to a lower incidence of relapse and superior overall survival... Reader Responses: What are the treatment options for this patient with aggressive blastoid mantle cell... Here’s how readers responded to a You Make the Call question about treatment options for a patient with aggressive blastoid mantle cell lymphoma and... You Make the Call: What are the treatment options for this patient with aggressive blastoid... This month, Alexey V. Danilov, MD, PhD, discusses treatment options for a patient with aggressive blastoid mantle cell lymphoma and high bilirubin. And don't forget to...